Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

OSE Immunotherapeutics

OSE Immunotherapeutics?uq=AFYHfsyn
2004 FOUNDED
PUBLIC STATUS
21-30 EMPLOYEES
OSE STOCK SYMBOL
1 INVESTMENTS
$4.37 SHARE PRICE (As of Tuesday Closing)
Description

Developer of immuno-oncology therapies designed to restore immune disorders. The company's immuno-oncology therapies act on effector and suppressor cells to stimulate or inhibit the body's immune response, enabling pharmaceutical companies to develop innovative drug candidates in immuno-oncology, autoimmune diseases and transplantation.

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
PAR
Primary Office
  • 22, Boulevard Benoni Goullin
  • 44200 Nantes
  • France

+33 02 00 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore OSE Immunotherapeutics’s full profile, request a free trial.

OSE Immunotherapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$3.91 - $5.76 $63M $4.31 -$0.82 12.2K 14.6M

OSE Immunotherapeutics Financials Summary

In Thousands,
USD
TTM
31-Dec-2017
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 47,374 47,374 94,439 76,907
Revenue 7,536 7,536 424 4
EBITDA (14,191) (14,191) 19,541 (6,088)
Net Income (11,845) (11,845) 22,860 (6,194)
Total Assets 92,801 92,801 94,177 18,581
Total Debt 5,853 5,853 1,862 1,071
Public Fundamental Data provided by Morningstar, Inc. disclaimer

OSE Immunotherapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore OSE Immunotherapeutics‘s full profile, request access.

Request full access to PitchBook

OSE Immunotherapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 24-Feb-2016 000000000000000000 000.00 Pharmaceuticals 000000000 0000000000 00.0
To view this company’s complete investment and acquisition history, request access »

OSE Immunotherapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore OSE Immunotherapeutics‘s full profile, request access.

Request full access to PitchBook

OSE Immunotherapeutics Executive Team (4)

Name Title Board
Seat
Contact
Info
Alexis Peyroles Chief Executive Officer
Bernard Vanhove Ph.D Chief Operating Officer, Research & Development & International Scientific Collaborations
Dominique Costantini Ph.D Co-Founder, Chairman & Director of Early Development

1 Former Executive

You’re viewing 3 of 4 executives. Get the full list »

OSE Immunotherapeutics Board Members (6)

Name Representing Role Since Contact
Info
00000000 00é00 00.0 Self Board Member 000 0000
000 000000000 Self Board Member 000 0000
0000-0000000 000000000 Self Board Member 000 0000
000000000 000000 Self Vice Chairman 000 0000
000000 0000000 00.0 Effimune Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 6 board members. Get the full list »